Pub Date : 2026-01-01Epub Date: 2025-09-17DOI: 10.1016/j.bpsgos.2025.100612
Gemma McKeon , Andrea Baker , Stefan Blum , David Gillis , Kerri Prain , Judith M. Greer , George Bruxner , Michael E. Benros , Sean Hatherill , Shuichi Suetani , Dan Siskind , Kate Murphy , Hitesh Joshi , Jackie Curtis , Brian O’Donoghue , Iain Macmillan , Eva Malacova , Anita Pelecanos , Patrick Waters , Belinda Lennox , James G. Scott
Background
Early detection of autoimmune psychosis (AP) mediated by antineuronal antibodies (Abs) is critical for achieving optimal clinical outcomes. However, evidence remains limited regarding who should be tested and how Ab-positive cases should be managed. In this large-scale study, we evaluated proposed clinical criteria for targeted Ab testing in psychiatric services and described the clinical course of seropositive patients.
Methods
Individuals with early psychosis (EP) or persistent psychosis (PP) were prospectively assessed with clinical criteria to determine high- or low-risk status for AP. Blood samples were collected for Ab testing using a fixed cell-based assay. Seropositive individuals were invited for detailed review, including clinical, functional, and cognitive assessments at baseline and a 12-month follow-up. Blood samples were collected from 754 individuals (EP: n = 352, PP: n = 402).
Results
Abs were present in 2.3% (17/754), including 3.4% (12/352) of patients with EP and 1.2% (5/402) of patients with PP. AP was confirmed in 2 cerebrospinal fluid (CSF)–positive high-risk individuals (total: 2/754, 0.3%; EP: 1/352, 0.3%; PP: 1/402, 0.2%). Both improved with immunotherapy. Although some low-risk patients were seropositive, none were diagnosed clinically with AP.
Conclusions
AP prevalence was low in this cohort. Targeted testing informed by clinical high-risk criteria successfully identified 2 immunotherapy-responsive AP cases. This approach appears feasible but requires further validation. People with psychosis and high-risk AP features should be considered for Ab testing in sera and CSF where indicated. Further research is required to embed targeted Ab testing into mental health services.
背景:抗神经元抗体(Abs)介导的自身免疫性精神病(AP)的检测对于获得最佳临床结果至关重要。然而,关于谁应该接受检测以及如何处理ab阳性病例的证据仍然有限。在这项大规模研究中,我们评估了精神科服务中靶向Ab检测的拟议临床标准,并描述了血清阳性患者的临床病程。方法采用临床标准对早期精神病(EP)或持续性精神病(PP)患者进行前瞻性评估,以确定AP的高风险或低风险状态。采用固定细胞法采集血样进行Ab检测。血清阳性个体被邀请进行详细的审查,包括临床、功能和认知评估基线和12个月的随访。共采集754例(EP: n = 352, PP: n = 402)血液样本。结果抗体阳性率为2.3%(17/754),其中EP患者阳性率为3.4% (12/352),PP患者阳性率为1.2%(5/402)。2例脑脊液(CSF)阳性高危人群中证实有AP(总数:2/754,0.3%;EP: 1/352, 0.3%; PP: 1/402, 0.2%)。两种情况在免疫治疗后都有所改善。尽管部分低危患者血清检测呈阳性,但临床均未诊断出ap。结论该队列中ap患病率较低。根据临床高危标准进行的靶向检测成功鉴定出2例免疫治疗反应性AP病例。这种方法似乎可行,但需要进一步验证。有精神病和高危AP特征的患者应考虑在血清和脑脊液中进行Ab检测。将有针对性的Ab型抗体检测纳入心理健康服务需要进一步的研究。
{"title":"Clinical Criteria to Guide Antineuronal Antibody Testing for People With Early and Persistent Psychosis Attending Mental Health Services","authors":"Gemma McKeon , Andrea Baker , Stefan Blum , David Gillis , Kerri Prain , Judith M. Greer , George Bruxner , Michael E. Benros , Sean Hatherill , Shuichi Suetani , Dan Siskind , Kate Murphy , Hitesh Joshi , Jackie Curtis , Brian O’Donoghue , Iain Macmillan , Eva Malacova , Anita Pelecanos , Patrick Waters , Belinda Lennox , James G. Scott","doi":"10.1016/j.bpsgos.2025.100612","DOIUrl":"10.1016/j.bpsgos.2025.100612","url":null,"abstract":"<div><h3>Background</h3><div>Early detection of autoimmune psychosis (AP) mediated by antineuronal antibodies (Abs) is critical for achieving optimal clinical outcomes. However, evidence remains limited regarding who should be tested and how Ab-positive cases should be managed. In this large-scale study, we evaluated proposed clinical criteria for targeted Ab testing in psychiatric services and described the clinical course of seropositive patients.</div></div><div><h3>Methods</h3><div>Individuals with early psychosis (EP) or persistent psychosis (PP) were prospectively assessed with clinical criteria to determine high- or low-risk status for AP. Blood samples were collected for Ab testing using a fixed cell-based assay. Seropositive individuals were invited for detailed review, including clinical, functional, and cognitive assessments at baseline and a 12-month follow-up. Blood samples were collected from 754 individuals (EP: <em>n</em> = 352, PP: <em>n</em> = 402).</div></div><div><h3>Results</h3><div>Abs were present in 2.3% (17/754), including 3.4% (12/352) of patients with EP and 1.2% (5/402) of patients with PP. AP was confirmed in 2 cerebrospinal fluid (CSF)–positive high-risk individuals (total: 2/754, 0.3%; EP: 1/352, 0.3%; PP: 1/402, 0.2%). Both improved with immunotherapy. Although some low-risk patients were seropositive, none were diagnosed clinically with AP.</div></div><div><h3>Conclusions</h3><div>AP prevalence was low in this cohort. Targeted testing informed by clinical high-risk criteria successfully identified 2 immunotherapy-responsive AP cases. This approach appears feasible but requires further validation. People with psychosis and high-risk AP features should be considered for Ab testing in sera and CSF where indicated. Further research is required to embed targeted Ab testing into mental health services.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100612"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-09-30DOI: 10.1016/j.bpsgos.2025.100623
Huimin Zhou , Kaini Qiao , Jingjing Zhou , Xuequan Zhu , Zhi Yang , Gang Wang , Yanyu Wang , Zhenxiang Zang
Background
Resting-state functional magnetic resonance imaging (rs-fMRI) is a powerful tool to reveal disrupted brain activity in major depressive disorder (MDD), but most studies have focused solely on low-frequency functional fluctuations, ignoring the fact that brain activity is composed of both low-frequency and high-frequency fluctuations. Therefore, we applied a novel approach, namely the power spectral slope (PSS), which captures the characteristics of both low- and high-frequency fluctuations to evaluate brain activity in MDD.
Methods
rs-fMRI data were collected from 109 patients with MDD (27.29 ± 7.11 years, 75 women) and 78 normal control participants (26.47 ± 6.19 years, 51 women). A subset of 52 patients with MDD also underwent rs-fMRI scanning after a 12-week antidepressant treatment (escitalopram/duloxetine). Both the baseline between-group comparison and follow-up within-group comparison were performed for PSS. A 2-sample t test was used for baseline comparison with a liberal Gaussian random-field correction. The follow-up comparison was tested with paired t test.
Results
Patients with MDD showed significantly more negative PSS compared with normal control participants in the ventral striatum and temporal pole. After treatment, PSS in the ventral striatum increased significantly toward normalization, whereas the temporal pole’s slope remained unchanged. No significant correlations were found between PSS and depression severity scores.
Conclusions
This study demonstrates that MDD is characterized by more negative PSS in key affective regions. The normalization effect of ventral striatum spectral slope following antidepressant treatment suggests a region-specific response. Taken together, the findings suggest that PSS may serve as a novel brain functional marker for MDD.
{"title":"Power Spectral Slope as a Novel Brain Functional Marker for Major Depressive Disorder","authors":"Huimin Zhou , Kaini Qiao , Jingjing Zhou , Xuequan Zhu , Zhi Yang , Gang Wang , Yanyu Wang , Zhenxiang Zang","doi":"10.1016/j.bpsgos.2025.100623","DOIUrl":"10.1016/j.bpsgos.2025.100623","url":null,"abstract":"<div><h3>Background</h3><div>Resting-state functional magnetic resonance imaging (rs-fMRI) is a powerful tool to reveal disrupted brain activity in major depressive disorder (MDD), but most studies have focused solely on low-frequency functional fluctuations, ignoring the fact that brain activity is composed of both low-frequency and high-frequency fluctuations. Therefore, we applied a novel approach, namely the power spectral slope (PSS), which captures the characteristics of both low- and high-frequency fluctuations to evaluate brain activity in MDD.</div></div><div><h3>Methods</h3><div>rs-fMRI data were collected from 109 patients with MDD (27.29 ± 7.11 years, 75 women) and 78 normal control participants (26.47 ± 6.19 years, 51 women). A subset of 52 patients with MDD also underwent rs-fMRI scanning after a 12-week antidepressant treatment (escitalopram/duloxetine). Both the baseline between-group comparison and follow-up within-group comparison were performed for PSS. A 2-sample <em>t</em> test was used for baseline comparison with a liberal Gaussian random-field correction. The follow-up comparison was tested with paired <em>t</em> test.</div></div><div><h3>Results</h3><div>Patients with MDD showed significantly more negative PSS compared with normal control participants in the ventral striatum and temporal pole. After treatment, PSS in the ventral striatum increased significantly toward normalization, whereas the temporal pole’s slope remained unchanged. No significant correlations were found between PSS and depression severity scores.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that MDD is characterized by more negative PSS in key affective regions. The normalization effect of ventral striatum spectral slope following antidepressant treatment suggests a region-specific response. Taken together, the findings suggest that PSS may serve as a novel brain functional marker for MDD.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100623"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Autism spectrum disorder (ASD) shows significant clinical variability, likely due to a combination of genetic and environmental factors. Preterm birth is a known risk factor for ASD, occurring in approximately 13% of diagnosed individuals. While genetic factors contribute to preterm birth in the general population, the relationship between genetic variation, preterm birth, and ASD heterogeneity remains unclear.
Methods
We investigated the genetic factors associated with preterm birth in 31,947 autistic individuals using data from the SPARK (Simons Foundation Powering Autism Research for Knowledge) sample. We conducted 3 ancestry-specific genome-wide association studies for African/African American, admixed American, and non-Finnish European ancestries, followed by a meta-analysis of 3308 preterm cases and 28,639 controls using METAL. Functional mapping and gene-based analyses were performed using FUMA, and genetic correlations were estimated using LDSC and Popcorn. Polygenic risk scores (PRSs) were computed with BridgePRS, using PRS of preterm birth in the general population.
Results
Our study identified ancestry-specific genetic loci associated with preterm birth in ASD cases. Although the meta-analysis results were not statistically significant, the estimated single nucleotide polymorphism heritability was 14%, indicating a meaningful contribution of common genetic variants. Across ancestry groups, preterm birth status was not significantly associated with PRSs for any psychiatric or medical conditions analyzed. However, polygenic liability to preterm birth in the general population was linked to several congenital anomalies after multiple testing adjustments.
Conclusions
These findings highlight the importance of diverse ancestries and early-life exposures in understanding ASD heterogeneity. Future research should replicate these findings in larger samples and explore rare variants associated with preterm birth to better understand the relationship between gestational duration and clinical and genetic differences in ASD.
自闭症谱系障碍(ASD)表现出显著的临床变异性,可能是遗传和环境因素共同作用的结果。早产是自闭症谱系障碍的一个已知危险因素,约13%的确诊个体发生早产。虽然遗传因素在一般人群中会导致早产,但遗传变异、早产和ASD异质性之间的关系尚不清楚。方法我们使用SPARK (Simons Foundation powered Autism Research for Knowledge)样本的数据,对31947名自闭症患者的早产相关遗传因素进行了调查。我们对非裔/非裔美国人、混血儿美国人和非芬兰血统的欧洲人进行了3项谱系特异性全基因组关联研究,随后使用METAL对3308例早产病例和28639例对照进行了荟萃分析。使用fua进行功能定位和基于基因的分析,并使用LDSC和Popcorn估计遗传相关性。使用BridgePRS计算多基因风险评分(PRSs),使用一般人群早产的PRSs。结果我们的研究确定了谱系特异性基因位点与ASD患者早产相关。虽然meta分析结果没有统计学意义,但估计的单核苷酸多态性遗传率为14%,表明常见遗传变异的贡献有意义。在整个祖先群体中,早产状况与任何精神或医学状况的PRSs分析没有显着关联。然而,在多次测试调整后,一般人群的多基因早产倾向与几种先天性异常有关。这些发现强调了不同的祖先和早期生活暴露对理解ASD异质性的重要性。未来的研究应该在更大的样本中复制这些发现,并探索与早产相关的罕见变异,以更好地了解妊娠期与ASD临床和遗传差异之间的关系。
{"title":"Autism Heterogeneity Related to Preterm Birth: Multi-Ancestry Results From the Simons Foundation Powering Autism Research for Knowledge Sample","authors":"Charikleia Chatzigeorgiou , Zeynep Asgel , Marina Natividad Avila , Behrang Mahjani , Vahe Khachadourian , Tade Souaiaia , Niamh Mullins , Magdalena Janecka","doi":"10.1016/j.bpsgos.2025.100614","DOIUrl":"10.1016/j.bpsgos.2025.100614","url":null,"abstract":"<div><h3>Background</h3><div>Autism spectrum disorder (ASD) shows significant clinical variability, likely due to a combination of genetic and environmental factors. Preterm birth is a known risk factor for ASD, occurring in approximately 13% of diagnosed individuals. While genetic factors contribute to preterm birth in the general population, the relationship between genetic variation, preterm birth, and ASD heterogeneity remains unclear.</div></div><div><h3>Methods</h3><div>We investigated the genetic factors associated with preterm birth in 31,947 autistic individuals using data from the SPARK (Simons Foundation Powering Autism Research for Knowledge) sample. We conducted 3 ancestry-specific genome-wide association studies for African/African American, admixed American, and non-Finnish European ancestries, followed by a meta-analysis of 3308 preterm cases and 28,639 controls using METAL. Functional mapping and gene-based analyses were performed using FUMA, and genetic correlations were estimated using LDSC and Popcorn. Polygenic risk scores (PRSs) were computed with BridgePRS, using PRS of preterm birth in the general population.</div></div><div><h3>Results</h3><div>Our study identified ancestry-specific genetic loci associated with preterm birth in ASD cases. Although the meta-analysis results were not statistically significant, the estimated single nucleotide polymorphism heritability was 14%, indicating a meaningful contribution of common genetic variants. Across ancestry groups, preterm birth status was not significantly associated with PRSs for any psychiatric or medical conditions analyzed. However, polygenic liability to preterm birth in the general population was linked to several congenital anomalies after multiple testing adjustments.</div></div><div><h3>Conclusions</h3><div>These findings highlight the importance of diverse ancestries and early-life exposures in understanding ASD heterogeneity. Future research should replicate these findings in larger samples and explore rare variants associated with preterm birth to better understand the relationship between gestational duration and clinical and genetic differences in ASD.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100614"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-09-20DOI: 10.1016/j.bpsgos.2025.100617
Yihe Ma , Haniyyah Sardar , Max E. Benabou , Angeline C. Yu , Allison R. Morningstar , R. Nicolas Fajardo , Isaac F. Kandil , Ethan T. Rogers , Anne Vassalli , Julie A. Kauer , William J. Giardino
Background
Alcohol use disorder (AUD) is characterized by compulsive alcohol consumption and negative emotional states during withdrawal, often perpetuating a cycle of addiction through arousal dysfunction. The hypocretin/orexin (HCRT) neuropeptide system is a key regulator of arousal that is implicated in these processes, particularly in its interactions with corticotropin-releasing factor (CRF) neurons within the bed nucleus of the stria terminalis (BNST).
Methods
Using CRF-specific genetic deletion of Hcrtr1 and/or Hcrtr2 receptors in mice combined with behavioral and electrophysiological approaches, we investigated the role of HCRT receptor signaling in CRF neurons in modulating alcohol intake, anxiety behaviors, and BNST excitability, with a focus on sex-specific differences.
Results
We found that deletion of Hcrtr1 significantly reduced alcohol intake, with sex-specific effects on BNST excitability and synaptic drive. CRF-specific Hcrtr2 deletion, while not affecting alcohol consumption, decreased baseline anxiety-like behaviors in males relative to females. Moreover, the double deletion of both HCRT receptors from CRF neurons led to reduced alcohol drinking in males (while tending to increase alcohol drinking in females) and dampened anxiety behaviors and BNST excitability in both sexes during protracted withdrawal.
Conclusions
These findings suggest that HCRT signaling in CRF neurons plays a critical role in the persistence of excessive alcohol consumption and the development of negative affective states, with distinct contributions from HcrtR1 and HcrtR2. The observed sex-specific differences underscore the need for tailored therapeutic approaches targeting the HCRT system in the treatment of AUD.
{"title":"Sex-Specific Effects of Hypocretin Receptor Signaling in Corticotropin-Releasing Factor Neurons on Alcohol Drinking, Anxiety, and Extended Amygdala Neuronal Excitability","authors":"Yihe Ma , Haniyyah Sardar , Max E. Benabou , Angeline C. Yu , Allison R. Morningstar , R. Nicolas Fajardo , Isaac F. Kandil , Ethan T. Rogers , Anne Vassalli , Julie A. Kauer , William J. Giardino","doi":"10.1016/j.bpsgos.2025.100617","DOIUrl":"10.1016/j.bpsgos.2025.100617","url":null,"abstract":"<div><h3>Background</h3><div>Alcohol use disorder (AUD) is characterized by compulsive alcohol consumption and negative emotional states during withdrawal, often perpetuating a cycle of addiction through arousal dysfunction. The hypocretin/orexin (HCRT) neuropeptide system is a key regulator of arousal that is implicated in these processes, particularly in its interactions with corticotropin-releasing factor (CRF) neurons within the bed nucleus of the stria terminalis (BNST).</div></div><div><h3>Methods</h3><div>Using CRF-specific genetic deletion of <em>Hcrt</em><em>r</em><em>1</em> and/or <em>Hcrt</em><em>r</em><em>2</em> receptors in mice combined with behavioral and electrophysiological approaches, we investigated the role of HCRT receptor signaling in CRF neurons in modulating alcohol intake, anxiety behaviors, and BNST excitability, with a focus on sex-specific differences.</div></div><div><h3>Results</h3><div>We found that deletion of <em>Hcrt</em><em>r</em><em>1</em> significantly reduced alcohol intake, with sex-specific effects on BNST excitability and synaptic drive. CRF-specific <em>Hcrt</em><em>r</em><em>2</em> deletion, while not affecting alcohol consumption, decreased baseline anxiety-like behaviors in males relative to females. Moreover, the double deletion of both HCRT receptors from CRF neurons led to reduced alcohol drinking in males (while tending to increase alcohol drinking in females) and dampened anxiety behaviors and BNST excitability in both sexes during protracted withdrawal.</div></div><div><h3>Conclusions</h3><div>These findings suggest that HCRT signaling in CRF neurons plays a critical role in the persistence of excessive alcohol consumption and the development of negative affective states, with distinct contributions from HcrtR1 and HcrtR2. The observed sex-specific differences underscore the need for tailored therapeutic approaches targeting the HCRT system in the treatment of AUD.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100617"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145419193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-08DOI: 10.1016/j.bpsgos.2025.100629
Ashraf Mahmud , Giovanni Hernandez , Fatme Abboud , Cecilia Flores
Background
Elevated expression of the guidance cue receptor gene DCC in the adult prefrontal cortex (PFC) is a hallmark of major depressive disorder. DCC receptors regulate neuronal connectivity and plasticity in adulthood. In male mice, Dcc knockout in the PFC promotes resilience to behavioral dysregulation following chronic social defeat stress (CSDS), whereas Dcc upregulation increases susceptibility. However, the underlying mechanisms remain to be elucidated.
Methods
We combined CSDS, behavioral tests (i.e., social interaction, nestlet shredding, and dark-light tests), retrograde neuronal tracing, and quantitative neuroanatomical analysis in adult male mice (N = 90) to investigate whether DCC receptors contribute to stress susceptibility/resilience by remodeling dendritic spine architecture of selective PFC neuronal networks.
Results
CSDS reduced both mature and newly formed spines on the apical, but not basal, dendrites of PFC pyramidal neurons. This effect was prevented by downregulating DCC receptors in these neurons, a manipulation that also prevented depression-like behaviors, suggesting a mechanistic link. DCC-expressing neurons in the PFC predominantly projected to the nucleus accumbens, and social defeat stress induced dendritic spine loss specifically in projections from the infralimbic PFC. Notably, knockout of DCC receptors in infralimbic PFC neurons projecting to the nucleus accumbens shell protected against stress-induced social avoidance.
Conclusions
DCC receptors may influence susceptibility or resilience to social stress–induced depression-like behaviors by altering the apical dendritic architecture of PFC pyramidal neurons, particularly those projecting to the nucleus accumbens shell. This mechanism may be at play in the neurobiology of depression, pointing to DCC receptors as promising therapeutic targets.
{"title":"Stress-Induced Dysregulation of the Guidance Cue Receptor DCC Alters Corticolimbic Circuit Architecture","authors":"Ashraf Mahmud , Giovanni Hernandez , Fatme Abboud , Cecilia Flores","doi":"10.1016/j.bpsgos.2025.100629","DOIUrl":"10.1016/j.bpsgos.2025.100629","url":null,"abstract":"<div><h3>Background</h3><div>Elevated expression of the guidance cue receptor gene <em>DCC</em> in the adult prefrontal cortex (PFC) is a hallmark of major depressive disorder. DCC receptors regulate neuronal connectivity and plasticity in adulthood. In male mice, <em>Dcc</em> knockout in the PFC promotes resilience to behavioral dysregulation following chronic social defeat stress (CSDS), whereas <em>Dcc</em> upregulation increases susceptibility. However, the underlying mechanisms remain to be elucidated.</div></div><div><h3>Methods</h3><div>We combined CSDS, behavioral tests (i.e., social interaction, nestlet shredding, and dark-light tests), retrograde neuronal tracing, and quantitative neuroanatomical analysis in adult male mice (<em>N</em> = 90) to investigate whether DCC receptors contribute to stress susceptibility/resilience by remodeling dendritic spine architecture of selective PFC neuronal networks.</div></div><div><h3>Results</h3><div>CSDS reduced both mature and newly formed spines on the apical, but not basal, dendrites of PFC pyramidal neurons. This effect was prevented by downregulating DCC receptors in these neurons, a manipulation that also prevented depression-like behaviors, suggesting a mechanistic link. DCC-expressing neurons in the PFC predominantly projected to the nucleus accumbens, and social defeat stress induced dendritic spine loss specifically in projections from the infralimbic PFC. Notably, knockout of DCC receptors in infralimbic PFC neurons projecting to the nucleus accumbens shell protected against stress-induced social avoidance.</div></div><div><h3>Conclusions</h3><div>DCC receptors may influence susceptibility or resilience to social stress–induced depression-like behaviors by altering the apical dendritic architecture of PFC pyramidal neurons, particularly those projecting to the nucleus accumbens shell. This mechanism may be at play in the neurobiology of depression, pointing to DCC receptors as promising therapeutic targets.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100629"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-10DOI: 10.1016/j.bpsgos.2025.100625
Jon E. Grant
{"title":"Rethinking Trichotillomania","authors":"Jon E. Grant","doi":"10.1016/j.bpsgos.2025.100625","DOIUrl":"10.1016/j.bpsgos.2025.100625","url":null,"abstract":"","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100625"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-04DOI: 10.1016/j.bpsgos.2025.100621
Laureta Gashi , Sophia Khom
{"title":"Engagement of the Paraventricular Nucleus of the Thalamus During Withdrawal-Related Learning: Implications for Alcohol Use Disorder","authors":"Laureta Gashi , Sophia Khom","doi":"10.1016/j.bpsgos.2025.100621","DOIUrl":"10.1016/j.bpsgos.2025.100621","url":null,"abstract":"","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100621"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145467528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-09-09DOI: 10.1016/j.bpsgos.2025.100609
Tine Van Bogaert , Martijn Figee , Brian H. Kopell , Andrew Smith , Jungho Cha , Ha Neul Song , Davide Momi , Zarghona Imtiaz , Sanjana Murthy , Sonia Olson , Elisa Xu , Helen Mayberg , Myles Mc Laughlin , Ki Sueng Choi , Allison C. Waters
Background
Deep brain stimulation (DBS) of the anterior limb of the internal capsule (ALIC) is an effective treatment for severe, treatment-resistant obsessive-compulsive disorder (OCD). However, optimizing lead placement and stimulation parameters remains a challenge. DBS evoked potentials (EPs) recorded with electroencephalography (EEG) during surgical lead placement could serve as intraoperative biomarkers for target engagement and clinical efficacy.
Methods
We obtained intraoperative EEG recordings on the forehead from 10 patients (2 nonresponders) undergoing ALIC DBS surgery for OCD. Monopolar stimulation at 2 Hz was delivered through all electrode contacts, and EEG EPs were analyzed in relation to stimulation contact, white matter connectivity to the prefrontal cortical regions of interest (assessed via probabilistic tractography), and reduction in symptom severity (assessed with the Yale-Brown Obsessive Compulsive Scale).
Results
We observed consistent DBS EPs with 3 oscillatory peaks (∼35, ∼75, and ∼120 ms) across all patients. EP amplitude varied across contacts, with the largest responses occurring when the location of stimulation overlapped with the preoperatively defined tractographic target. Higher EP amplitudes recorded on the forehead correlated with greater white matter connectivity to the ventromedial prefrontal cortex/orbitofrontal cortex and ventrolateral prefrontal cortex. Treatment nonresponders exhibited less consistent EP waveforms across lead contacts.
Conclusions
These findings suggest that intraoperative EPs provide valuable insights into ALIC DBS target engagement. EP characteristics may serve as biomarkers to refine DBS targeting and predict clinical response, offering a potential tool for optimizing DBS therapy for OCD.
{"title":"Electrophysiological Biomarkers Reflect Target Engagement and Response Using Deep Brain Stimulation for Obsessive-Compulsive Disorder","authors":"Tine Van Bogaert , Martijn Figee , Brian H. Kopell , Andrew Smith , Jungho Cha , Ha Neul Song , Davide Momi , Zarghona Imtiaz , Sanjana Murthy , Sonia Olson , Elisa Xu , Helen Mayberg , Myles Mc Laughlin , Ki Sueng Choi , Allison C. Waters","doi":"10.1016/j.bpsgos.2025.100609","DOIUrl":"10.1016/j.bpsgos.2025.100609","url":null,"abstract":"<div><h3>Background</h3><div>Deep brain stimulation (DBS) of the anterior limb of the internal capsule (ALIC) is an effective treatment for severe, treatment-resistant obsessive-compulsive disorder (OCD). However, optimizing lead placement and stimulation parameters remains a challenge. DBS evoked potentials (EPs) recorded with electroencephalography (EEG) during surgical lead placement could serve as intraoperative biomarkers for target engagement and clinical efficacy.</div></div><div><h3>Methods</h3><div>We obtained intraoperative EEG recordings on the forehead from 10 patients (2 nonresponders) undergoing ALIC DBS surgery for OCD. Monopolar stimulation at 2 Hz was delivered through all electrode contacts, and EEG EPs were analyzed in relation to stimulation contact, white matter connectivity to the prefrontal cortical regions of interest (assessed via probabilistic tractography), and reduction in symptom severity (assessed with the Yale-Brown Obsessive Compulsive Scale).</div></div><div><h3>Results</h3><div>We observed consistent DBS EPs with 3 oscillatory peaks (∼35, ∼75, and ∼120 ms) across all patients. EP amplitude varied across contacts, with the largest responses occurring when the location of stimulation overlapped with the preoperatively defined tractographic target. Higher EP amplitudes recorded on the forehead correlated with greater white matter connectivity to the ventromedial prefrontal cortex/orbitofrontal cortex and ventrolateral prefrontal cortex. Treatment nonresponders exhibited less consistent EP waveforms across lead contacts.</div></div><div><h3>Conclusions</h3><div>These findings suggest that intraoperative EPs provide valuable insights into ALIC DBS target engagement. EP characteristics may serve as biomarkers to refine DBS targeting and predict clinical response, offering a potential tool for optimizing DBS therapy for OCD.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"6 1","pages":"Article 100609"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145419190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-08-11DOI: 10.1016/j.bpsgos.2025.100589
Isaac Z. Pope , Sidhant Chopra , Alexander Holmes , Shona M. Francey , Brian O’Donoghue , Vanessa L. Cropley , Barnaby Nelson , Hok Pan Yuen , Kelly Allott , Mario Alvarez-Jimenez , Susy Harrigan , Christos Pantelis , Andrew Thompson , Stephen J. Wood , Patrick D. McGorry , Alex Fornito
Background
Clinical outcomes following the first episode of psychosis (FEP) are highly heterogeneous across patients. The identification of prognostic biomarkers would greatly facilitate personalized treatments. Patients with psychosis often display brainwide disruptions of interregional functional coupling (FC), with some being linked to symptom severity and remission. Thus, FC may have prognostic potential for people experiencing psychosis.
Methods
Fifty-five antipsychotic-naïve patients with FEP (51% female, ages 15–25 years) were randomized to receive either antipsychotic or placebo tablets for 6 months alongside psychosocial interventions. Functional magnetic resonance imaging was conducted at baseline and after 3 months to evaluate whether baseline FC or 3-month change in FC could predict 6- and 12-month changes in symptoms and functioning, quantified using the Brief Psychiatric Rating Scale and the Social and Occupational Functioning Assessment Scale, respectively. We considered 3 different cross-validated prediction algorithms: 1) connectome-based predictive modeling, 2) kernel ridge regression, and 3) multilayer meta-matching. Each prediction model comprised 35 to 49 individuals.
Results
All models showed poor performance in predicting patients’ 6- and 12-month changes in symptoms and functioning (all rmean < 0.3), and no model achieved significance via permutation testing (all p > .05).
Conclusions
Our findings suggest that brainwide measures of FC may not be suitable for predicting extended clinical outcomes over a 6- to 12-month period in patients with FEP.
{"title":"Functional Coupling and Longitudinal Outcome Prediction in First-Episode Psychosis","authors":"Isaac Z. Pope , Sidhant Chopra , Alexander Holmes , Shona M. Francey , Brian O’Donoghue , Vanessa L. Cropley , Barnaby Nelson , Hok Pan Yuen , Kelly Allott , Mario Alvarez-Jimenez , Susy Harrigan , Christos Pantelis , Andrew Thompson , Stephen J. Wood , Patrick D. McGorry , Alex Fornito","doi":"10.1016/j.bpsgos.2025.100589","DOIUrl":"10.1016/j.bpsgos.2025.100589","url":null,"abstract":"<div><h3>Background</h3><div>Clinical outcomes following the first episode of psychosis (FEP) are highly heterogeneous across patients. The identification of prognostic biomarkers would greatly facilitate personalized treatments. Patients with psychosis often display brainwide disruptions of interregional functional coupling (FC), with some being linked to symptom severity and remission. Thus, FC may have prognostic potential for people experiencing psychosis.</div></div><div><h3>Methods</h3><div>Fifty-five antipsychotic-naïve patients with FEP (51% female, ages 15–25 years) were randomized to receive either antipsychotic or placebo tablets for 6 months alongside psychosocial interventions. Functional magnetic resonance imaging was conducted at baseline and after 3 months to evaluate whether baseline FC or 3-month change in FC could predict 6- and 12-month changes in symptoms and functioning, quantified using the Brief Psychiatric Rating Scale and the Social and Occupational Functioning Assessment Scale, respectively. We considered 3 different cross-validated prediction algorithms: 1) connectome-based predictive modeling, 2) kernel ridge regression, and 3) multilayer meta-matching. Each prediction model comprised 35 to 49 individuals.</div></div><div><h3>Results</h3><div>All models showed poor performance in predicting patients’ 6- and 12-month changes in symptoms and functioning (all <em>r</em><em><sub>mean</sub></em> < 0.3), and no model achieved significance via permutation testing (all <em>p</em> > .05).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that brainwide measures of FC may not be suitable for predicting extended clinical outcomes over a 6- to 12-month period in patients with FEP.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"5 6","pages":"Article 100589"},"PeriodicalIF":3.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-09-02DOI: 10.1016/j.bpsgos.2025.100605
Luis C. Farhat , Kayoko Isomura , Ralf Kuja-Halkola , Isabell Brikell , Zheng Chang , Brian M. D’Onofrio , Henrik Larsson , Paul Lichtenstein , Lorena Fernández de la Cruz , Anna Sidorchuk , David Mataix-Cols
Background
Trichotillomania is an understudied psychiatric disorder characterized by repeated hair-pulling resulting in hair loss. Little is known about the risk of problematic substance use in this patient group. In this nationwide matched cohort study, we investigated the association between trichotillomania and substance-related problems.
Methods
We linked various nationwide administrative and clinical registers in Sweden. Among 12,015,664 individuals living in the country from January 1, 1997, to December 31, 2020, we identified 1136 individuals with an ICD-10 diagnosis of trichotillomania at age ≥10 years (86.4% female, median age at first diagnosis 23.8 years [interquartile range 13.3–34.9 years]) and matched them with 11,360 unaffected individuals. The outcome was broadly defined as substance-related problems (alcohol- and drug-related disorders, suspected criminal offenses, and deaths). Stratified Cox proportional hazards regression was used to determine hazard ratios (HRs) for the association between trichotillomania and any substance-related problems.
Results
Over a mean follow-up period of 6 years, substance-related problems were recorded for 137 (12.1%) individuals with trichotillomania and 399 (3.5%) matched individuals (crude incidence rates per 1000 person-years of 21.6 and 5.6, respectively). After controlling for sociodemographic covariates and parental substance-related problems, trichotillomania was associated with an increased relative risk of substance-related problems (HR, 3.12; 95% CI, 2.53–3.85). Adjusting also for comorbid psychiatric history did not meaningfully change the findings.
Conclusions
Individuals with trichotillomania had a 3-fold increased risk of substance-related problems compared with unaffected individuals. Future research should examine the mechanisms underlying this association and inform the clinical management of the dual diagnoses.
{"title":"Trichotillomania and Risk of Alcohol- and Drug-Related Problems","authors":"Luis C. Farhat , Kayoko Isomura , Ralf Kuja-Halkola , Isabell Brikell , Zheng Chang , Brian M. D’Onofrio , Henrik Larsson , Paul Lichtenstein , Lorena Fernández de la Cruz , Anna Sidorchuk , David Mataix-Cols","doi":"10.1016/j.bpsgos.2025.100605","DOIUrl":"10.1016/j.bpsgos.2025.100605","url":null,"abstract":"<div><h3>Background</h3><div>Trichotillomania is an understudied psychiatric disorder characterized by repeated hair-pulling resulting in hair loss. Little is known about the risk of problematic substance use in this patient group. In this nationwide matched cohort study, we investigated the association between trichotillomania and substance-related problems.</div></div><div><h3>Methods</h3><div>We linked various nationwide administrative and clinical registers in Sweden. Among 12,015,664 individuals living in the country from January 1, 1997, to December 31, 2020, we identified 1136 individuals with an ICD-10 diagnosis of trichotillomania at age ≥10 years (86.4% female, median age at first diagnosis 23.8 years [interquartile range 13.3–34.9 years]) and matched them with 11,360 unaffected individuals. The outcome was broadly defined as substance-related problems (alcohol- and drug-related disorders, suspected criminal offenses, and deaths). Stratified Cox proportional hazards regression was used to determine hazard ratios (HRs) for the association between trichotillomania and any substance-related problems.</div></div><div><h3>Results</h3><div>Over a mean follow-up period of 6 years, substance-related problems were recorded for 137 (12.1%) individuals with trichotillomania and 399 (3.5%) matched individuals (crude incidence rates per 1000 person-years of 21.6 and 5.6, respectively). After controlling for sociodemographic covariates and parental substance-related problems, trichotillomania was associated with an increased relative risk of substance-related problems (HR, 3.12; 95% CI, 2.53–3.85). Adjusting also for comorbid psychiatric history did not meaningfully change the findings.</div></div><div><h3>Conclusions</h3><div>Individuals with trichotillomania had a 3-fold increased risk of substance-related problems compared with unaffected individuals. Future research should examine the mechanisms underlying this association and inform the clinical management of the dual diagnoses.</div></div>","PeriodicalId":72373,"journal":{"name":"Biological psychiatry global open science","volume":"5 6","pages":"Article 100605"},"PeriodicalIF":3.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145267143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}